Search results
1 wrz 2024 · FINEARTS-HF is a randomized, double-blind, placebo-controlled, multicenter, event-driven Phase III trial investigating the efficacy and safety of KERENDIA® (finerenone) for the reduction of risk of cardiovascular death and heart failure (HF) events in patients with a diagnosis of symptomatic heart failure (New York Heart Association class II-IV)...
In this webinar from SCI's Fine Chemicals Group and Young Chemists' Panel, Dr Lars Bärfacker discusses the development of dihydronaphthyridine finerenone, a therapeutic for counteracting negative...
5 sie 2024 · Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. By targeting MR and renin-angiotensin-aldosterone system (RAAS) overactivation, finerenone addresses hallmarks of HF with a LVEF ≥40%, such as progressive fibrosis.
24 wrz 2022 · Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist. Finerenone is thought to have lower risk of hyperkalemia and renal issues compared to other MRAs.
3 dni temu · Berlin, September 27, 2024 – Bayer announced today that new subgroup analyses from the Phase III FINEARTS-HF trial evaluating finerenone (Kerendia™) in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≥ 40% will be presented at the Heart Failure Society of America (HFSA) Annual Meeting 2024.. Data being presented at HFSA include:
5 sie 2024 · Finerenone (Kerendia), a nonsteroidal, selective mineralocorticoid receptor antagonist (nsMRA) can reduce the composite of cardiovascular death and total heart failure events in patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), according to topline results from FINEARTS-HF. The randomized trial is the first to show a ...
22 cze 2023 · In the finerenone Phase III program for CKD associated with T2D with over 13,000 people, FIDELIO-DKD and FIGARO-DKD showed finerenone reduced the risk of chronic kidney disease progression.
